A L F van der Kooi1,2,3, M M van den Heuvel-Eibrink2,3, A van Noortwijk4, S J C M M Neggers5, S M F Pluijm2,3, E van Dulmen-den Broeder6, W van Dorp4, J S E Laven4. 1. Division of Reproductive Medicine, Department of Obstetrics and Gynaecology, Erasmus MC-University Medical Center Rotterdam, PO Box 2040, 3000 CA Rotterdam, the Netherlands a.vanderkooi@erasmusmc.nl. 2. Princess Maxima Center for Pediatric Oncology, Lundlaan 6, 3584 EA Utrecht, the Netherlands. 3. Department of Paediatric Oncology/Haematology, Erasmus MC-Sophia Children's Hospital, Wytemaweg 40, 3015 GJ Rotterdam, the Netherlands. 4. Division of Reproductive Medicine, Department of Obstetrics and Gynaecology, Erasmus MC-University Medical Center Rotterdam, PO Box 2040, 3000 CA Rotterdam, the Netherlands. 5. Department of Endocrinology, Erasmus Medical Center, 's-Gravendijkwal 230, 3015 CE Rotterdam, the Netherlands. 6. Department of Paediatrics, Division of Paediatric Oncology/Haematology, VU University Medical Center, PO Box 7057, 1007 MB Amsterdam, the Netherlands.
Abstract
STUDY QUESTION: Is the long-term decline of ovarian function, as reflected by a decrease in serum anti-Müllerian hormone (AMH) concentration, accelerated over time in female childhood cancer survivors (CCS) as compared to healthy women of the same age? SUMMARY ANSWER: The median decline of AMH levels in long-term female CCS is not accelerated and similar to that observed in healthy controls. WHAT IS KNOWN ALREADY: Gonadal function is compromised in female CCS treated with chemotherapy and/or radiation therapy. Ovarian function is most compromised in survivors treated with total body irradiation, abdominal or pelvic irradiation, stem cell transplantation or high doses of alkylating agents. STUDY DESIGN SIZE, DURATION: Longitudinal single-centre cohort study in 192 CCS in Rotterdam, The Netherlands, between 2001 and 2014. PARTICIPANTS/MATERIALS, SETTING, METHODS: Serum AMH levels of 192 adult female CCS were assessed, at least five years after cessation of treatment and at a follow-up visit with a median of 3.2 years (range: 2.1-6.0) later and were compared to the age-based P50 of AMH in healthy controls. MAIN RESULTS AND THE ROLE OF CHANCE: Median AMH levels were below the P50 at both visit 1 (-0.59 µg/L) and at visit 2 (-0.22 µg/L). In women with a sustained ovarian function (AMH > 1.0 µg/L), the decline in AMH is similar to that in the normal population (difference in decline per year: -0.07 µg/L (range: -2.86 to 4.92), P = 0.75). None of the treatment modalities was correlated with a significant acceleration of decline of AMH per year. LIMITATIONS REASONS FOR CAUTION: We selected CCS that visited our late effect outpatient clinic and who had two AMH levels available. It is conceivable that women without any apparent late effects of treatment as well as women with extreme late effects, which might be the ones with the largest impact on ovarian function, could be more likely to be lost to follow-up. However, general characteristics did not differ between the included and excluded patients. WIDER IMPLICATIONS OF THE FINDINGS: While prospective longitudinal research is required to strengthen our findings, they may help physicians to counsel female CCS about their expected reproductive lifespan. STUDY FUNDING/COMPETING INTERESTS: A.L.F.v.d.K., M.M.v.d.H.-E. and S.M.F.P. are supported by FP7-PanCare LIFE. J.S.E.L. has received grants from the following companies (in alphabetical order): Ferring, Merck Serono, Merck Sharp and Dome, Organon, Serono, Shering Plough and Shering. The other authors have no conflicts of interest to declare.
STUDY QUESTION: Is the long-term decline of ovarian function, as reflected by a decrease in serum anti-Müllerian hormone (AMH) concentration, accelerated over time in female childhood cancer survivors (CCS) as compared to healthy women of the same age? SUMMARY ANSWER: The median decline of AMH levels in long-term female CCS is not accelerated and similar to that observed in healthy controls. WHAT IS KNOWN ALREADY: Gonadal function is compromised in female CCS treated with chemotherapy and/or radiation therapy. Ovarian function is most compromised in survivors treated with total body irradiation, abdominal or pelvic irradiation, stem cell transplantation or high doses of alkylating agents. STUDY DESIGN SIZE, DURATION: Longitudinal single-centre cohort study in 192 CCS in Rotterdam, The Netherlands, between 2001 and 2014. PARTICIPANTS/MATERIALS, SETTING, METHODS: Serum AMH levels of 192 adult female CCS were assessed, at least five years after cessation of treatment and at a follow-up visit with a median of 3.2 years (range: 2.1-6.0) later and were compared to the age-based P50 of AMH in healthy controls. MAIN RESULTS AND THE ROLE OF CHANCE: Median AMH levels were below the P50 at both visit 1 (-0.59 µg/L) and at visit 2 (-0.22 µg/L). In women with a sustained ovarian function (AMH > 1.0 µg/L), the decline in AMH is similar to that in the normal population (difference in decline per year: -0.07 µg/L (range: -2.86 to 4.92), P = 0.75). None of the treatment modalities was correlated with a significant acceleration of decline of AMH per year. LIMITATIONS REASONS FOR CAUTION: We selected CCS that visited our late effect outpatient clinic and who had two AMH levels available. It is conceivable that women without any apparent late effects of treatment as well as women with extreme late effects, which might be the ones with the largest impact on ovarian function, could be more likely to be lost to follow-up. However, general characteristics did not differ between the included and excluded patients. WIDER IMPLICATIONS OF THE FINDINGS: While prospective longitudinal research is required to strengthen our findings, they may help physicians to counsel female CCS about their expected reproductive lifespan. STUDY FUNDING/COMPETING INTERESTS: A.L.F.v.d.K., M.M.v.d.H.-E. and S.M.F.P. are supported by FP7-PanCare LIFE. J.S.E.L. has received grants from the following companies (in alphabetical order): Ferring, Merck Serono, Merck Sharp and Dome, Organon, Serono, Shering Plough and Shering. The other authors have no conflicts of interest to declare.
Authors: H Irene Su; Brian Kwan; Brian W Whitcomb; Ksenya Shliakhsitsava; Andrew C Dietz; Shaylyn S Stark; Elena Martinez; Patrick M Sluss; Mary D Sammel; Loki Natarajan Journal: J Clin Endocrinol Metab Date: 2020-08-01 Impact factor: 5.958
Authors: Hanneke M van Santen; Marry M van den Heuvel-Eibrink; Marianne D van de Wetering; W Hamish Wallace Journal: Horm Res Paediatr Date: 2019-01-31 Impact factor: 2.852
Authors: Anne-Lotte L F van der Kooi; Marloes van Dijk; Linda Broer; Marleen H van den Berg; Joop S E Laven; Flora E van Leeuwen; Cornelis B Lambalk; Annelies Overbeek; Jacqueline J Loonen; Helena J van der Pal; Wim J Tissing; Birgitta Versluys; Dorine Bresters; Catharina C M Beerendonk; Cécile R Ronckers; Margriet van der Heiden-van der Loo; Gertjan L Kaspers; Andrica C H de Vries; Leslie L Robison; Melissa M Hudson; Wassim Chemaitilly; Julianne Byrne; Claire Berger; Eva Clemens; Uta Dirksen; Jeanette Falck Winther; Sophie D Fosså; Desiree Grabow; Riccardo Haupt; Melanie Kaiser; Tomas Kepak; Jarmila Kruseova; Dalit Modan-Moses; Saskia M F Pluijm; Claudia Spix; Oliver Zolk; Peter Kaatsch; Jesse H Krijthe; Leontien C Kremer; Yutaka Yasui; Russell J Brooke; André G Uitterlinden; Marry M van den Heuvel-Eibrink; Eline van Dulmen-den Broeder Journal: Hum Reprod Date: 2021-03-18 Impact factor: 6.918
Authors: Anne-Lotte L F van der Kooi; Eva Clemens; Linda Broer; Oliver Zolk; Julianne Byrne; Helen Campbell; Marleen van den Berg; Claire Berger; Gabriele Calaminus; Uta Dirksen; Jeanette Falck Winther; Sophie D Fosså; Desiree Grabow; Riccardo Haupt; Melanie Kaiser; Tomas Kepak; Leontien Kremer; Jarmila Kruseova; Dalit Modan-Moses; Andreas Ranft; Claudia Spix; Peter Kaatsch; Joop S E Laven; Eline van Dulmen-den Broeder; André G Uitterlinden; Marry M van den Heuvel-Eibrink Journal: BMC Cancer Date: 2018-09-26 Impact factor: 4.430